A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Pablo C OkhuysenMayur S RameshThomas LouieNino KiknadzeJulian Torre-CisnerosClaudia Murta de OliveiraChristophe Van SteenkisteAlena StychneuskayaKevin W GareyJulia Garcia-DiazJianling LiEsther DuperchyBetty Y ChangJuthamas SukbuntherngJose G MontoyaLori StylesFong ClowDanelle JamesErik R DubberkeMark H WilcoxPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Although ridinilazole did not meet superiority in SCR, ridinilazole greatly reduced rCDI and preserved microbiome diversity and SBAs compared with vancomycin. These findings suggest that treatment of CDI with ridinilazole results in an earlier recovery of gut microbiome health. Clinical Trials Registration.Ri-CoDIFy 1 and 2: NCT03595553 and NCT03595566.